A5026165592- Ocular Diseases and Behçet’s Syndrome
- Retinal Diseases and Treatments
- Retinal and Optic Conditions
- Glaucoma and retinal disorders
- Retinal Imaging and Analysis
- Ocular Surface and Contact Lens
- Cytomegalovirus and herpesvirus research
- Systemic Lupus Erythematosus Research
- Vasculitis and related conditions
- HIV Research and Treatment
- Herpesvirus Infections and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Cell Adhesion Molecules Research
- Ocular Infections and Treatments
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Lymphoma Diagnosis and Treatment
- Allergic Rhinitis and Sensitization
- Corneal surgery and disorders
- Retinal Development and Disorders
- Neurological Disorders and Treatments
- Immune Response and Inflammation
- Retinal and Macular Surgery
- Immunotherapy and Immune Responses
- Otitis Media and Relapsing Polychondritis
- T-cell and B-cell Immunology
Doheny Eye Institute
1998-2019
Allergan (United States)
2008-2017
Midwest Eye Institute
2016-2017
Indiana University – Purdue University Indianapolis
2017
Allergan (Ireland)
2001-2016
Creative Commons
2016
Kaplan Medical Center
2016
Peregrine Eye and Laser Institute
2016
Universidade de São Paulo
2016
Retina Specialists
2016
To evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex, DEX implant) 0.7 0.35 mg in treatment patients with diabetic macular edema (DME).Two randomized, multicenter, masked, sham-controlled, phase III clinical trials identical protocols were conducted. Data pooled for analysis.Patients (n = 1048) DME, best-corrected visual acuity (BCVA) 20/50 to 20/200 Snellen equivalent, central retinal thickness (CRT) ≥300 μm by optical coherence tomography.Patients randomized a...
Purpose.: To determine the pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone (DEX) intravitreal implant (Ozurdex; Allergan, Inc.). Methods.: Thirty-four male monkeys (Macaca fascicularis) received bilateral 0.7-mg DEX implants. Blood, vitreous humor, retina samples were collected at predetermined intervals up to 270 days after administration. was quantified by liquid chromatography–tandem mass spectrometry, cytochrome P450 3A8 (CYP3A8) gene expression analyzed...
Our website uses cookies to enhance your experience. By continuing use our site, or clicking "Continue," you are agreeing Cookie Policy | Continue JAMA Ophthalmology HomeNew OnlineCurrent IssueFor Authors Podcast Publications Network Open Cardiology Dermatology Health Forum Internal Medicine Neurology Oncology Otolaryngology–Head & Neck Surgery Pediatrics Psychiatry Archives of (1919-1959) JN Learning / CMESubscribeJobsInstitutions LibrariansReprints Permissions Terms Use Privacy...
<h3>Objective</h3> To evaluate a dexamethasone intravitreous drug delivery system (DDS) in patients with persistent (≥90 days despite treatment) macular edema. <h3>Methods</h3> This 6-month study randomized 315 edema best-corrected visual acuity (BCVA) of 20/40 to 20/200 the eye observation or single treatment DDS, 350 700 μg. <h3>Main Outcome Measures</h3> Proportion achieving BCVA improvement 10 more letters 15 letters, safety measures, change fluorescein angiographic leakage, and central...
To evaluate the safety and efficacy of Ozurdex (dexamethasone intravitreal implant) 0.7 mg in treatment diabetic macular edema vitrectomized eyes.This was a prospective, multicenter, open-label, 26-week study. Fifty-five patients with treatment-resistant history previous pars plana vitrectomy study eye received single injection 0.7-mg dexamethasone implant. The primary outcome measure change central retinal thickness from baseline to Week 26 measured by optical coherence tomography.The mean...
To determine whether early visual acuity response to ranibizumab in diabetic macular edema is associated with long-term outcome.Post hoc analysis of randomized controlled trial data.Pooled data from the plus prompt and deferred laser treatment arms Diabetic Retinopathy Clinical Research Network's Protocol I study were used explore relationship between (week 12) late (weeks 52-156) (mean change baseline best-corrected [CFB BCVA]; categorized improvement [<5, 5-9, or ≥10 Early Treatment Study...
To evaluate the clinical usefulness of tumor necrosis factor (TNF) inhibitors in patients with inflammatory eye disease that is resistant to conventional immunosuppressive therapies.Sixteen (4 males and 12 females aged 7 78 years) who received etanercept (n = 14) or infliximab 2) for either associated joint were studied retrospectively determine effect these medications on their ocular inflammation.Nine cases uveitis scleritis treated. Systemic diagnoses included rheumatoid arthritis 8),...
To investigate the safety and efficacy of etanercept in treatment uveitis associated with juvenile idiopathic arthritis (JIA).Children who met American College Rheumatology diagnostic criteria for JIA active uveitis, had anterior chamber cells >/=1+ or requiring topical corticosteroid >/=3 times daily, were on a stable regimen eligible. Study participants received (0.4 mg/kg) placebo administered subcutaneously twice weekly 6 months. All open-label an additional months.Five patients 7...
To evaluate the safety and potential therapeutic activity of humanized anti-IL-2 receptor mAb (Daclizumab) therapy in treatment patients with severe, sight-threatening, intermediate posterior noninfectious uveitis, a nonrandomized, open-label, pilot study was performed. Patients uveitis were treated minimum 20 mg prednisone, cyclosporine, antimetabolites, or any combination these agents eligible. weaned off their systemic immunosuppressive according to standardized schedule, while ultimately...
the National Institutes of Health (NIH) in Bethesda, Maryland.The conference provided an opportunity to gather a diverse group more than 200 experts from both academic ophthalmology and ophthalmic pharmaceutical industry, including laboratory researchers clinicians, discuss recent advances delivery systems that convey ocular drugs posterior segment how these might be successfully used commercial products.The two-day meeting comprised following nine sessions: (1) eye anatomy barriers drug...
PURPOSE Primary CNS lymphoma (PCNSL) and primary intraocular (IOL) are usually treated with radiation therapy alone or in combination chemotherapy. The neurotoxicity of these treatments can be substantial. This study attempts to define the toxicity efficacy treatment this disease chemotherapy alone. PATIENTS AND METHODS Fourteen nonimmunocompromised patients were accrued a regimen that incorporated 24-hour infusion high-dose methotrexate total dose 8.4 g/m2 leucovorin rescue; thiotepa 35...
Purpose To ascertain the incidence of cystoid macular edema (CME) after phacoemulsification and its relationship to blood–aqueous barrier damage visual acuity. Setting A British teaching hospital. Methods prospective trial was performed document CME routine with continuous curvilinear capsulorhexis. LogMAR acuity laser flare were measured using KOWA FC 1000 cell–flare meter preoperatively 1, 14, 30, 60 days postoperatively. At day 60, a standardized fluorescein angiogram graded by masked...
Diagnosis of primary central nervous system lymphoma (PCNSL) is usually made by identifying malignant lymphocytes in the brain, cerebrospinal fluid (CSF), or vitreous. However, these cells are few and friable, misdiagnosis can occur, even properly prepared specimens. Recent data suggest that levels interleukin 10 (IL-10) elevated serum vitreous patients with non-Hodgkin lymphoma; 6 (IL-6) intraocular inflammation unrelated to a neoplasm. We investigated whether PCNSL involving CSF associated...
<h3>Objective</h3> To compare bimatoprost with timolol maleate in patients glaucoma or ocular hypertension. <h3>Methods</h3> In 2 identical, multicenter, randomized, double-masked, 1-year clinical trials, were treated 0.03% once daily (QD) (n = 474), twice (BID) 483), 0.5% BID 241). <h3>Main Outcome Measures</h3> Diurnal intraocular pressure (IOP) at 8 AM, 10 and 4 PM safety variables (IOP was also measured selected sites). <h3>Results</h3> Bimatoprost QD provided significantly lower mean...
Purpose.: To evaluate dexamethasone pharmacokinetics after implantation of a sustained-release (DEX) intravitreal implant in nonvitrectomized and vitrectomized eyes. Methods.: The right eyes 25 rabbits underwent vitrectomy; contralateral served as nonvitrectomy controls. 0.7-mg DEX was injected into both eyes, drug concentrations were determined the vitreous humor retina for 31 days (on 2, 8, 15, 22, 31). Results.: present at least days. There no statistically significant differences...
In Brief Purpose: To evaluate the occurrence, management, and clinical significance of increases in intraocular pressure (IOP) patients with diabetic macular edema treated dexamethasone intravitreal implant (DEX implant). Methods: Randomized, multicenter, 3-year, Phase III study. Patients (N = 1,048) were randomized to DEX 0.7-mg, 0.35-mg, or sham procedure retreatment allowed at ≥6-month intervals (seven injections maximum). Results: groups, respectively, ≥10-mmHg IOP from baseline occurred...